-
1
-
-
0036895290
-
Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma
-
DOI 10.1200/JCO.2002.05.111
-
Zisman A, Pantuck AJ, Wieder J, Chao DH, Dorey F, Said JW, deKernion JB, Figlin RA and Belldegrun AS: Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 20: 4559-4566, 2002. (Pubitemid 35402959)
-
(2002)
Journal of Clinical Oncology
, vol.20
, Issue.23
, pp. 4559-4566
-
-
Zisman, A.1
Pantuck, A.J.2
Wieder, J.3
Chao, D.H.4
Dorey, F.5
Said, J.W.6
DeKernion, J.B.7
Figlin, R.A.8
Belldegrun, A.S.9
-
2
-
-
4644303268
-
Innovations and challenges in renal cancer: Consensus statement from the first international conference
-
DOI 10.1158/1078-0432.CCR-040720
-
Atkins MB, Avigan DE, Bukowski RM, et al: Innovations and challenges in renal cancer: consensus statement from the first international conference. Clin Cancer Res 10: 6277S-6281S, 2004. (Pubitemid 39287478)
-
(2004)
Clinical Cancer Research
, vol.10
, Issue.18 II
-
-
Atkins, M.B.1
Avigan, D.E.2
Bukowski, R.M.3
Childs, R.W.4
Dutcher, J.P.5
Eisen, T.G.6
Figlin, R.A.7
Finke, J.H.8
Flanigan, R.C.9
George, D.J.10
Goldberg, S.N.11
Gordon, M.S.12
Iliopoulos, O.13
Kaelin Jr., W.G.14
Linehan, W.M.15
Lipton, A.16
Motzer, R.J.17
Novick, A.C.18
Stadler, W.M.19
Teh, B.T.20
Yang, J.C.21
King, L.22
more..
-
3
-
-
33846148701
-
Sorafenib in advanced clear-cell renal-cell carcinoma
-
DOI 10.1056/NEJMoa060655
-
Escudier B, Eisen T, Stadler WM, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125-134, 2007. (Pubitemid 46089673)
-
(2007)
New England Journal of Medicine
, vol.356
, Issue.2
, pp. 125-134
-
-
Escudier, B.1
Eisen, T.2
Stadler, W.M.3
Szczylik, C.4
Oudard, S.5
Siebels, M.6
Negrier, S.7
Chevreau, C.8
Solska, E.9
Desai, A.A.10
Rolland, F.11
Demkow, T.12
Hutson, T.E.13
Gore, M.14
Freeman, S.15
Schwartz, B.16
Shan, M.17
Simantov, R.18
Bukowski, R.M.19
-
4
-
-
60849120120
-
A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer
-
Heng DY, Chi KN, Murray N, Jin T, Garcia JA, Bukowski RM, Rini BI and Kollmannsberger C: A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer. Cancer 115: 776-783, 2009.
-
(2009)
Cancer
, vol.115
, pp. 776-783
-
-
Heng, D.Y.1
Chi, K.N.2
Murray, N.3
Jin, T.4
Garcia, J.A.5
Bukowski, R.M.6
Rini, B.I.7
Kollmannsberger, C.8
-
5
-
-
68949145218
-
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma
-
Motzer RJ, Hutson TE, Tomczak P, et al: Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27: 3584-3590, 2009.
-
(2009)
J Clin Oncol
, vol.27
, pp. 3584-3590
-
-
Motzer, R.J.1
Hutson, T.E.2
Tomczak, P.3
-
6
-
-
19744365702
-
A small molecule-kinase interaction map for clinical kinase inhibitors
-
DOI 10.1038/nbt1068
-
Fabian MA, Biggs WH, III, Treiber DK, et al: A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 23: 329-336, 2005. (Pubitemid 41094421)
-
(2005)
Nature Biotechnology
, vol.23
, Issue.3
, pp. 329-336
-
-
Fabian, M.A.1
Biggs III, W.H.2
Treiber, D.K.3
Atteridge, C.E.4
Azimioara, M.D.5
Benedetti, M.G.6
Carter, T.A.7
Ciceri, P.8
Edeen, P.T.9
Floyd, M.10
Ford, J.M.11
Galvin, M.12
Gerlach, J.L.13
Grotzfeld, R.M.14
Herrgard, S.15
Insko, D.E.16
Insko, M.A.17
Lai, A.G.18
Lelias, J.-M.19
Mehta, S.A.20
Milanov, Z.V.21
Velasco, A.M.22
Wodicka, L.M.23
Patel, H.K.24
Zarrinkar, P.P.25
Lockhart, D.J.26
more..
-
7
-
-
4944249117
-
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
-
DOI 10.1158/0008-5472.CAN-04-1443
-
Wilhelm SM, Carter C, Tang L, et al: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/ MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64: 7099-7109, 2004. (Pubitemid 39331023)
-
(2004)
Cancer Research
, vol.64
, Issue.19
, pp. 7099-7109
-
-
Wilhelm, S.M.1
Carter, C.2
Tang, L.3
Wilkie, D.4
McNabola, A.5
Rong, H.6
Chen, C.7
Zhang, X.8
Vincent, P.9
McHugh, M.10
Cao, Y.11
Shujath, J.12
Gawlak, S.13
Eveleigh, D.14
Rowley, B.15
Liu, L.16
Adnane, L.17
Lynch, M.18
Auclair, D.19
Taylor, I.20
Gedrich, R.21
Voznesensky, A.22
Riedl, B.23
Post, L.E.24
Bollag, G.25
Trail, P.A.26
more..
-
8
-
-
68949199667
-
Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: Results from a multicenter study
-
Zhang H, Dong B, Lu JJ, Yao X, Zhang S, Dai B, Shen Y, Zhu Y, Ye D and Huang Y: Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: results from a multicenter study. BMC Cancer 9: 249-256, 2009.
-
(2009)
BMC Cancer
, vol.9
, pp. 249-256
-
-
Zhang, H.1
Dong, B.2
Lu, J.J.3
Yao, X.4
Zhang, S.5
Dai, B.6
Shen, Y.7
Zhu, Y.8
Ye, D.9
Huang, Y.10
-
9
-
-
79952671531
-
Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model
-
Yuen JS, Sim MY, Siml HG, Chong TW, Lau WK, Cheng CW and Huynh H: Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model. Br J Cancer 104: 941-947, 2011.
-
(2011)
Br J Cancer
, vol.104
, pp. 941-947
-
-
Yuen, J.S.1
Sim, M.Y.2
Siml, H.G.3
Chong, T.W.4
Lau, W.K.5
Cheng, C.W.6
Huynh, H.7
-
10
-
-
71349084002
-
AZD6244 enhances the antitumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC)
-
Huynh H, Ngo VC, Koong HN, et al: AZD6244 enhances the antitumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC). J Hepat 52: 79-87, 2010.
-
(2010)
J Hepat
, vol.52
, pp. 79-87
-
-
Huynh, H.1
Ngo, V.C.2
Koong, H.N.3
-
11
-
-
33846812600
-
Xenografts of human hepatocellular carcinoma: A useful model for testing drugs
-
Huynh H, Soo KC, Chow PK, Panasci L and Tran E: Xenografts of human hepatocellular carcinoma: A useful model for testing drugs. Clin Cancer Res 12: 4306-4314, 2006.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 4306-4314
-
-
Huynh, H.1
Soo, K.C.2
Chow, P.K.3
Panasci, L.4
Tran, E.5
-
12
-
-
79959307577
-
Targeting receptor tyrosine kinase pathways in hepatocellular carcinoma
-
Huynh H, Ong RW, Li PY, Lee SS, Yang S, Chong LW, Luu DA, Jong CT and Lam IW: Targeting receptor tyrosine kinase pathways in hepatocellular carcinoma. Anticancer Agents Med Chem 11: 560-575, 2011.
-
(2011)
Anticancer Agents Med Chem
, vol.11
, pp. 560-575
-
-
Huynh, H.1
Ong, R.W.2
Li, P.Y.3
Lee, S.S.4
Yang, S.5
Chong, L.W.6
Luu, D.A.7
Jong, C.T.8
Lam, I.W.9
-
13
-
-
77956084780
-
Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program
-
Bukowski RM, Stadler WM, McDermott DF, et al: Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program. Oncology 78: 340-347, 2010.
-
(2010)
Oncology
, vol.78
, pp. 340-347
-
-
Bukowski, R.M.1
Stadler, W.M.2
McDermott, D.F.3
-
14
-
-
80051588648
-
A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer
-
Hidalgo M, Bruckheimer E, Rajeshkumar NV, Garrido-Laguna I, Oliveira ED, Rubio-Viqueira B, Strawn S, Wick MJ, Martell J and Sidransky D: A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther 10: 1311-1316, 2011.
-
(2011)
Mol Cancer Ther
, vol.10
, pp. 1311-1316
-
-
Hidalgo, M.1
Bruckheimer, E.2
Rajeshkumar, N.V.3
Garrido-Laguna, I.4
Oliveira, E.D.5
Rubio-Viqueira, B.6
Strawn, S.7
Wick, M.J.8
Martell, J.9
Sidransky, D.10
|